TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of participants who breast-feed
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Uterine rupture
Endpoint domain: Adverse events/effects
Primary endpoint: Electrical Potential at Acupuncture points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Craving for ATS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness score of the fall preventing intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication Dosing Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Transient Dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in Days of Headache Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Intensity of Pain in a Migraine Attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response on the combined dexamethasone corticotropin-releasing hormone test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Threshold of High to Low Frequency Ratio (Threshold HLFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implant and peri-implant tissues health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved Sustained Virological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Demonstrated Virological Relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Device-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Sinus Symptom Scores (SN-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sinus Symptom Scores (SNOT-20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma calcium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of sepsis within 7 days
Endpoint domain: Adverse events/effects
Primary endpoint: Ease of Use and Comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subject Global Aesthetic Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: % of time in the set SpO2 target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Pain Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: recurrent vitreous hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: postoperative retinal detachment rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: development of intraoperative retinal breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Change in recognition of study participant to depression care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Elevated Liver Function Post-baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of Participants With a Decrease in Hemoglobin Post-baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Increases in Total, Conjugated and Non-conjugated Bilirubin Post-baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Adverse Events (AEs) by Seriousness and Relationship to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced Pulmonary Edema With the Presence of Veno-occlusive Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjective effects of cannabis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of life deterioration > 10%
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diffusion magnetic resonance imaging analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of cyclosporine and its metabolites in colonic mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral density of vesicular acetylcholine transporter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Organ density of vesicular acetylcholine transporter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of vesicular acetylcholine transporter compared to cognitive profile and autonomic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the pentavalent vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of the pentavalent vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: absolute marginal discrepancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with significant pain relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of subjects free of Major Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects free of Grade II, III or IV mitral regurgitation, mitral valve replacement or mitral valve reintervention
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Plasma HIV RNA on Day 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With HIV RNA Levels Below 50 Copies/mL at Week 240
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of Participants Reporting no Cocaine Craving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cocaine Use as Measured by Urine Drug Screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of FMT in patients with Crohn's disease
Endpoint domain: Adverse events/effects
Primary endpoint: Recipients' fecal microbial diversity after FMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in plasma total homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Digit Vigilance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood Glucose level test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weighted proportion of non-immune related hypothyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Identification and validation of cancer biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Respiratory events (desaturation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Respiratory events (chin lift)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Respiratory events (jaw thrust)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Respiratory events (mask-bag ventilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AKI incidence
Endpoint domain: Mortality/survival
Primary endpoint: Dialysis requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Expression of CD8+CD39+PD1+ lymphocytes infiltrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in score of the Nine Hole Peg Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermal threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants receiving additional units
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nipple fissure healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RANKL/OPG ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: presence of osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: Social Responsiveness Scale (SRS) Edition 2
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Aberrant Behavior Checklist (ABC) Edition 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine craving
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Drug use during outpatient maintenance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of late radiotherapy toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with de-escalation of antifungal treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vertigo visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Cardiac and Cerebrovascular Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radial Artery Occlusion (RAO)
Endpoint domain: Adverse events/effects
Primary endpoint: thrombosis (total thrombus formation analysis system)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of All-Cause Mortality and Cardiovascular Outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Composite of Cardiovascular Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of subjects with all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects with respiratory failure
Endpoint domain: Mortality/survival
Primary endpoint: Submental laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cmax of LOR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-last of LOR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration profiles of LOR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of TA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-last of TA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration profiles of TA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASMase activity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver iron content (LIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time spent in the target glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prosthetic wear time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Complete or partial pain response after radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cases of second line treatment usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Levels of differentially methylated insulin DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Severity-weighted Total Days of ARI Illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary incontinence during sexual activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Penis shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orgasmic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Axial plaque stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cap thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants with at Least 1 Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with at Least 1 Treatment Emergent Serious Adverse Event (TESAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Female Participants who are Pregnant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants With Pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of carbon dioxide rebreathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days of school missed per month
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change From Baseline in Hypoparathyroidism Symptom Diary (HypoPT-SD) Symptom Subscale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of MR in quantifying liver iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Moorong Self-Efficacy Scale (MSES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Analyte Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve to the Last Quantifiable Sampling Time Point (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-density Lipoprotein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low-density Lipoprotein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of glucose polymers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of ≥ 0.5 log10 Copies/mL in HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of linear measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visfatin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Impairment Questionnaire (WIQ) score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ankle-Brachial Index (ABI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in treadmill test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the proportion of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain in nominated joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Attempt's Success Rate of Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Completing 5 Behavioral Treatment Sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence With Bedtime Recommendations
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Adherence to Rise Time Recommendations
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Non-adherence to Nighttime Stimulus Control
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Functional Independence measure (FIM) at the admission
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional Independence measure (FIM) 1-month hospitalization
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional Independence measure (FIM) at the discharge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of phosphorus 31 released during muscle exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of plasma allantoin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Maximal Oxygen Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Maximal Oxygen Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Time Reaching on Maximal Test (tVO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Adverse Events (AE) or Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Treatment Effects on Basal Morning Cortisol and Adrenocorticotropic Hormone (ACTH) Stimulated Cortisol Levels at Week 4 in Comparison With Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: postoperative outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Differences in Mean cGMP Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain with walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference between arterial and end-tidal carbon dioxide pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Heart rate response to upright position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: development of cardiovascular diseases and complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total venous embolic load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of corneal surface in the recipient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of corneal surface in the donor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers predicting drug response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers predicting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in average overall finger joints pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lateral scapular slide test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fugl-Meyer Assessment (FMA) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: scapular balance angle (SBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Opioid Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at 1 Week (Visual Analogue Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at 4 Weeks (Visual Analogue Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at 12 Weeks (Visual Analogue Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between HPV tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants diagnosed with HPV infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants That Were Successfully Rehydrated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevated urine NGAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quantitative Electroencephalography Absolute Delta Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quantitative Electroencephalography Absolute Alpha Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: quantification of radical species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TOP2α expressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with poor prognosis
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with documented desaturations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Best recovery of logMAR visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lumbar Pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intramyocellular lipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes